Jonathan Lim Acquires 48,000 Shares of BOLD

Jonathan Lim recently purchased 48,000 shares of BOLD on June 15, 2026. This insider buy was not part of a pre-planned trading program. The stock was trading around $1.41 at the time of the transaction.

Insider Buying and Selling at Boundless Bio, Inc.

Several insiders were active at BOLD on June 15, 2026. In addition to Jonathan Lim's purchase, James Christensen, Jennifer Lew, and Nancy Whiting each bought 32,000 shares. Earlier in the year, on January 23, 2026, David Hinkle, the Senior VP, Finance, Controller and Treasurer, acquired 140,000 shares, and Zachary Hornby, the President & CEO, purchased 600,000 shares.

Other Institutional Activity in BOLD

Among BOLD's institutional investors, FMR LLC increased its holdings by 11,433 shares, reaching a total of 2,695,455 shares valued at about $2,965,000. Citadel Advisors LLC reduced its position by 11,773 shares, now holding 1,342,131 shares worth approximately $1,476,344. Sectoral Asset Management Inc maintained its position with 678,574 shares valued at $746,431. Stonepine Capital Management, LLC cut its stake by 112,389 shares to 597,682 shares, worth around $657,450. Vanguard Capital Management LLC initiated a new position with 597,192 shares valued at about $656,911.

Analysts Set New Price Targets

On August 11, 2025, HC Wainwright & Co. maintained its 'buy' rating for BOLD with a target price of $4.00. Previously, on June 2, 2025, the firm initiated coverage with a 'buy' rating and a $5.00 target. Leerink Partners downgraded the stock to 'hold' with a $3.00 target on May 28, 2025. Earlier, they had initiated a 'buy' rating with a $25.00 target on April 22, 2024. Piper Sandler also initiated a 'buy' rating with a $20.00 target on the same day.

About BOLD

BOLD operates in the healthcare sector, focusing on innovative treatments and therapies. The company is involved in developing solutions for unmet medical needs, aiming to enhance patient outcomes. Based in the United States, BOLD is led by a team of experienced professionals committed to advancing healthcare innovations.

Bottom Line

Jonathan Lim's recent purchase of BOLD shares highlights ongoing insider interest in the company. Institutional investors have shown mixed activity, with some increasing and others reducing their stakes. Analysts have varied opinions, with recent price targets reflecting both optimism and caution. Investors track such insider and institutional moves for insights, but it's important to remember that these filings are retrospective and may not indicate current positions.